Celyad SA (CYAD): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYAD Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CYAD is 0 -- better than just 7.03% of US stocks.
- CYAD's price/sales ratio is 9,931.73; that's higher than the P/S ratio of 99.81% of US stocks.
- Revenue growth over the past 12 months for Celyad Oncology SA comes in at -99.83%, a number that bests merely 0.65% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CYAD, based on their financial statements, market capitalization, and price volatility, are CRSP, TGTX, VHC, VNRX, and RPTX.
- Visit CYAD's SEC page to see the company's official filings. To visit the company's web site, go to www.celyad.com.
CYAD Stock Price Chart Interactive Chart >
CYAD Price/Volume Stats
| Current price | $4.38 | 52-week high | $10.31 |
| Prev. close | $4.27 | 52-week low | $3.76 |
| Day low | $4.27 | Volume | 3,100 |
| Day high | $4.40 | Avg. volume | 34,421 |
| 50-day MA | $4.32 | Dividend yield | N/A |
| 200-day MA | $6.23 | Market Cap | 67.86M |
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Latest CYAD News From Around the Web
Below are the latest news stories about Celyad Oncology SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.
Celyad Oncology Announces September 2021 Conferences ScheduleMONT-SAINT-GUIBERT, Belgium, September 01, 2021--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021: |
Celyad Oncology SA (CYAD) CEO Filippo Petti on Q2 2021 Results - Earnings Call TranscriptCelyad Oncology SA (CYAD) Q2 2021 Results Conference Call August 5, 2021 08:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Filippo Petti - Chief Executive Officer David Gilham - Chief Scientific Officer Stephen Rubino - Chief Business Officer Charlie Morris - Chief Medical Officer Conference Call Participants Olga... |
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights•Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next clinical update expected by year-end 2021 •Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 with KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on-track to begin in the fourth quarter of 2021 •IND-enabling studies in progress for first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-20 |
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)MONT-SAINT-GUIBERT, Belgium, July 30, 2021--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on July 30, 2021, a capital increase of 300,000 new shares of the Company to Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. As a result, the Company’s share capi |
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)MONT-SAINT-GUIBERT, Belgium, July 30, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on July 30, 2021, a capital increase of 300,000 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 54,956,224.33 EUR and |
CYAD Price Returns
| 1-mo | 5.29% |
| 3-mo | -19.78% |
| 6-mo | -39.59% |
| 1-year | -52.23% |
| 3-year | -84.37% |
| 5-year | -79.23% |
| YTD | -43.85% |
| 2020 | -25.14% |
| 2019 | -42.62% |
| 2018 | -57.87% |
| 2017 | 142.68% |
| 2016 | -67.47% |
Continue Researching CYAD
Want to see what other sources are saying about Celyad Sa's financials and stock price? Try the links below:Celyad Sa (CYAD) Stock Price | Nasdaq
Celyad Sa (CYAD) Stock Quote, History and News - Yahoo Finance
Celyad Sa (CYAD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...